574 related articles for article (PubMed ID: 12023945)
1. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1).
MacKenzie SJ; Baillie GS; McPhee I; MacKenzie C; Seamons R; McSorley T; Millen J; Beard MB; van Heeke G; Houslay MD
Br J Pharmacol; 2002 Jun; 136(3):421-33. PubMed ID: 12023945
[TBL] [Abstract][Full Text] [Related]
2. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region.
McCahill A; McSorley T; Huston E; Hill EV; Lynch MJ; Gall I; Keryer G; Lygren B; Tasken K; van Heeke G; Houslay MD
Cell Signal; 2005 Sep; 17(9):1158-73. PubMed ID: 15905070
[TBL] [Abstract][Full Text] [Related]
3. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
4. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).
Collins DM; Murdoch H; Dunlop AJ; Charych E; Baillie GS; Wang Q; Herberg FW; Brandon N; Prinz A; Houslay MD
Cell Signal; 2008 Dec; 20(12):2356-69. PubMed ID: 18845247
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579.
Hill EV; Sheppard CL; Cheung YF; Gall I; Krause E; Houslay MD
Cell Signal; 2006 Nov; 18(11):2056-69. PubMed ID: 16973330
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation.
Sette C; Conti M
J Biol Chem; 1996 Jul; 271(28):16526-34. PubMed ID: 8663227
[TBL] [Abstract][Full Text] [Related]
7. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.
Terry R; Cheung YF; Praestegaard M; Baillie GS; Huston E; Gall I; Adams DR; Houslay MD
Cell Signal; 2003 Oct; 15(10):955-71. PubMed ID: 12873709
[TBL] [Abstract][Full Text] [Related]
8. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.
Hoffmann R; Wilkinson IR; McCallum JF; Engels P; Houslay MD
Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):139-49. PubMed ID: 9639573
[TBL] [Abstract][Full Text] [Related]
9. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK).
Baillie G; MacKenzie SJ; Houslay MD
Mol Pharmacol; 2001 Nov; 60(5):1100-11. PubMed ID: 11641439
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.
Shepherd M; McSorley T; Olsen AE; Johnston LA; Thomson NC; Baillie GS; Houslay MD; Bolger GB
Biochem J; 2003 Mar; 370(Pt 2):429-38. PubMed ID: 12441002
[TBL] [Abstract][Full Text] [Related]
11. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.
Li X; Vadrevu S; Dunlop A; Day J; Advant N; Troeger J; Klussmann E; Jaffrey E; Hay RT; Adams DR; Houslay MD; Baillie GS
Biochem J; 2010 Apr; 428(1):55-65. PubMed ID: 20196770
[TBL] [Abstract][Full Text] [Related]
12. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.
Murthy KS; Zhou H; Makhlouf GM
Am J Physiol Cell Physiol; 2002 Mar; 282(3):C508-17. PubMed ID: 11832336
[TBL] [Abstract][Full Text] [Related]
13. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
14. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
Baillie GS; Sood A; McPhee I; Gall I; Perry SJ; Lefkowitz RJ; Houslay MD
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):940-5. PubMed ID: 12552097
[TBL] [Abstract][Full Text] [Related]
15. The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases.
Richter W; Conti M
J Biol Chem; 2004 Jul; 279(29):30338-48. PubMed ID: 15131123
[TBL] [Abstract][Full Text] [Related]
16. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
17. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells.
Millen J; MacLean MR; Houslay MD
Eur J Cell Biol; 2006 Jul; 85(7):679-91. PubMed ID: 16458997
[TBL] [Abstract][Full Text] [Related]
19. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.
Hoffmann R; Baillie GS; MacKenzie SJ; Yarwood SJ; Houslay MD
EMBO J; 1999 Feb; 18(4):893-903. PubMed ID: 10022832
[TBL] [Abstract][Full Text] [Related]
20. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
